10X Genomics (TXG) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with TXG
Recent news

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
TXG

Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
TXG

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
TXG

3 Analysts, 3 Trades to Make Today
3 Analysts, 3 Trades to Make Today
TXG
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 49.50
- MACD 12/26/9
- 4.99
- EMA 9 of MACD
- 6.58
- MACD histogram
- -1.59
- SMA 50
- $67.73
- Price above SMA 50
- EMA 50
- $69.39
- Price above EMA 50
- SMA 200
- $36.09
- Price above SMA 200
- EMA 200
- $41.33
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 9 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.23 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
TXG

Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
TXG

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
TXG

3 Analysts, 3 Trades to Make Today
3 Analysts, 3 Trades to Make Today
TXG

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
TXG

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
TXG

SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
TXG

10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG

10x Genomics Q2 Earnings Call Highlights
10x Genomics Q2 Earnings Call Highlights
TXG

10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
TXG
News tone: automated (AI) classification of the article's content, not a price prediction.
About 10X Genomics
We are a life science technology company building products to interrogate, understand and master biology. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Serge Saxonov Ph.D. | Co-Founder, CEO & Director | 1977 |
| Dr. Benjamin J. Hindson Ph.D. | Co-Founder, President, Chief Scientific Officer & Director | 1975 |
| Mr. Adam S. Taich | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | 1975 |
| Mr. Jim Goodrich | Chief of Global Operations | — |
| Mr. Michael Schnall-Levin Ph.D. | Founding Scientist & CTO | — |
| Ms. Cassie Corneau | Manager of Investor Relations & Strategic Finance | — |
| Dr. Randy Wu | General Counsel and Secretary | — |
| Ms. Mennah Moustafa | Chief Commercial Officer | — |
| Mr. Jens Durruthy | Associate Director of Product Management | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 49.50
- MACD 12/26/9
- 4.99
- EMA 9 of MACD
- 6.58
- MACD histogram
- -1.59
- SMA 50
- $67.73
- Price above SMA 50
- EMA 50
- $69.39
- Price above EMA 50
- SMA 200
- $36.09
- Price above SMA 200
- EMA 200
- $41.33
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $40.00
- Average
- $74.78
- High
- $110.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.4 | -6.7 | +3.2 | |||||||||
| 2022 | -34.0 | -18.1 | -6.0 | -41.1 | +0.7 | -1.9 | -14.3 | -17.2 | -11.7 | -4.1 | +37.0 | -7.9 |
| 2023 | +32.6 | -0.1 | +19.6 | -2.3 | +0.1 | +5.0 | +11.0 | -16.7 | -23.7 | -12.9 | +26.8 | +22.3 |
| 2024 | -23.3 | +7.0 | -17.6 | -21.0 | -16.7 | -12.3 | +11.2 | +18.6 | -2.0 | -24.8 | -2.6 | -12.8 |
| 2025 | +5.7 | -26.0 | -11.4 | -4.6 | +17.7 | +22.5 | +11.5 | +7.1 | -12.6 | +10.1 | +37.3 | -9.8 |
| 2026 | +21.5 | +15.5 | -8.3 | +0.0 | +26.2 | +29.6 | +21.0 | +32.8 | +50.7 | -12.9 |



